
Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma
The PARP inhibitor olaparib (Lynparza) in combination with temozolomide (Temodar) did not demonstrate superiority vs investigator’s choice of pazopanib (Votrient) or trabectedin (Yondelis) for the treatment of patients with advanced uterine leiomyosarcoma …